2025/02/01 by Robert Hnasko, Alice V. Lin, Jeffery A. McGarvey +1 · 1 voice
Medicine · Engineering · #SARS-CoV-2 detection and testing #Biosensors and Analytical Detection #SARS-CoV-2 and COVID-19 Research
paper · pdf · doi:10.1111/1751-7915.70117
openalex publication_date 2025/02/01 · openalex created_date 2025/02/25 · openalex updated_date 2026/07/31
ABSTRACT Immunoassays represent sensitive, easy‐to‐use, and cost‐effective tests useful for the detection of the SARS‐CoV‐2 virus. In this manuscript, we report on the binding specificity of a pair of novel monoclonal antibodies (MAbs) generated against the SARS‐CoV‐2 nucleocapsid protein (NP) and their development into sensitive sandwich enzyme‐linked immunosorbent assays (sELISA) and a lateral flow immunoassay (LFIA). Binding of these MAbs to hCoVs is limited to variants of SARS‐CoV‐2 and SARS‐CoV NP. Chemiluminescent and absorbance spectroscopy sELISAs report a limit of detection (LOD) for the SARS‐CoV‐2 B.1.1.529 NP variant at 15 pg/mL, and the LFIA using a red‐dyed 200 nm particle at 10 ng/mL. The sELISA exhibits broad SARS‐CoV‐2 viral variant detection with assay LOD for SARS‐CoV‐2 B.1.1.529 virus at 1.4 × 10 5 genome copies per mL ( p ≤ 0.001). The availability of these MAbs should facilitate continued investment in the commercial development of immunoassays to increase global SARS‐CoV‐2 detection technologies.